Highlights of SNO & EANO 2022 Annual Meetings

Highlights of SNO-EANO 2022: Tuesday February 14, 2023, at 12:30pm-1:30pm EST

Complimentary Registration!

Registration is free and limited to the first 1,000 participants. All SNO webinars are recorded, so if you miss one, you will be able to view it on-demand through the Neuro-Oncology Academy. 

Please email olivia@soc-neuro-onc.org for technical issues. 

Target Audience

Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates, and Nursing Professionals.

Learning Objectives

  • Discover antibody drug conjugates as a novel therapeutic strategy against brain tumors.
  • Analyse recent clinical trials on HER2+ brain metastasis.
  • Discover key aspects for future trial designs
  • Explore cancer neuroscience and the link to the immune system
  • Analyze Immunotherapy clinical trial results in glioblastoma treatment
  • Compare genomics and tumor evolution in the treatment of IDH mutant gliomas
  • Identify novel mechanism of resistance in brain tumors
Course summary
Available credit: 
  • 1.00 Attendance
Course opens: 
Course expires: 

Upcoming Events: 




Pim J French
Integrative molecular analysis of matched primary and recurrent IDH-mutant astrocytoma; an update from the GLASS-NL consortium

Erasmus University


Roel Verhaak
The longitudinal evolutionary trajectory of oligodendroglioma is driven by treatment-associated genetic alterations

The Jackson Laboratory

Frank Winkler
Disconnecting multicellular networks to tackle resistance in glioma
University Hospital Heidelberg
Hideho Okada
Glioma-induced neuronal remodeling promotes regional immunosuppression.
University of California, San Francisco

Matthias Preusser
ADC in HER2+ brain metastasis

Medical University of Vienna

Linda Liau
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial
University of California, Los Angeles


Nancy LinDana Farber Cancer Institute, Harvard Medical School
Roberta RudaUniversity and City of Health and Science Hospital, Turin, Italy

SNO -EANO Leadership:

Priscilla BrastianosMassachusetts General Hospital, Harvard Medical School
Albert KimWashington University St. Louis School of Medicine
Tracy BatchelorBrigham and Women’s Hospital
Susan ShortUniversity of Leeds
Michael PlattenMedical Faculty Mannheim, Heidelberg University
Manuel ValienteCentro Nacional de Investigaciones Oncologicas




Available Credit

  • 1.00 Attendance


Please login or register to take this course.

To register for this webinar, please follow these steps:

  1. If you have a Neuro-Oncology Academy account, select Login. If you do not yet have an account, select Register to create your FREE account. If you are a SNO member, select Login and on the next screen login under the “Society for Neuro-Oncology login.”
  2. Select Take Course. Answer the additional registration questions, then select Take Course.

We hope that this update makes the webinar viewing and credit claiming processes easier for you! Please don't hesitate to reach out to us at olivia@soc-neuro-onc.org with any questions.